Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
OncoGenex Technologies Inc in collaboration with Isis Pharmaceuticals Inc is developing OGX-011, an intravenously administered clusterin-inhibiting antisense oligonucleotide, to potentially sensitize solid tumors that are resistant to conventional cancer therapeutics. Phase II clinical trials of OGX-011 in combination with chemotherapeutic drugs are underway in NSCLC, prostate and breast cancer.
Schmitz
Gerd
G
University of Regensburg, Institute of Clinical Chemistry and Laboratory Medicine, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany. gerd.schmitz@klinik.uni-regensburg.de
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D051152:Clusterin / Q000037:antagonists & inhibitors* / Q000235:genetics*; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D020319:Oligodeoxyribonucleotides, Antisense / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D013329:Structure-Activity Relationship
C495242:CLU protein, human; D051152:Clusterin; D020319:Oligodeoxyribonucleotides, Antisense